Cracking the estrogen receptor's posttranslational code in breast tumors
- PMID: 21680538
- DOI: 10.1210/er.2010-0016
Cracking the estrogen receptor's posttranslational code in breast tumors
Abstract
Estrogen signaling pathways, because of their central role in regulating the growth and survival of breast tumor cells, have been identified as suitable and efficient targets for cancer therapies. Agents blocking estrogen activity are already widely used clinically, and many new molecules have entered clinical trials, but intrinsic or acquired resistance to treatment limits their efficacy. The basic molecular studies underlying estrogen signaling have defined the critical role of estrogen receptors (ER) in many aspects of breast tumorigenesis. However, important knowledge gaps remain about the role of posttranslational modifications (PTM) of ER in initiation and progression of breast carcinogenesis. Whereas major attention has been focused on the phosphorylation of ER, many other PTM (such as acetylation, ubiquitination, sumoylation, methylation, and palmitoylation) have been identified as events modifying ER expression and stability, subcellular localization, and sensitivity to hormonal response. This article will provide an overview of the current and emerging knowledge on ER PTM, with a particular focus on their deregulation in breast cancer. We also discuss their clinical relevance and the functional relationship between PTM. A thorough understanding of the complete picture of these modifications in ER carcinogenesis might not only open new avenues for identifying new markers for prognosis or prediction of response to endocrine therapy but also could promote the development of novel therapeutic strategies.
Similar articles
-
Sex hormone receptors in breast cancer.Vitam Horm. 2013;93:99-133. doi: 10.1016/B978-0-12-416673-8.00001-0. Vitam Horm. 2013. PMID: 23810004 Review.
-
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.Breast. 2011 Oct;20 Suppl 3:S42-9. doi: 10.1016/S0960-9776(11)70293-4. Breast. 2011. PMID: 22015292 Review.
-
[Post-translational modifications modulate estrogen receptor alpha activity in breast tumors].Med Sci (Paris). 2010 Jun-Jul;26(6-7):636-40. doi: 10.1051/medsci/2010266-7636. Med Sci (Paris). 2010. PMID: 20619167 Review. French.
-
Estrogen signaling and prediction of endocrine therapy.Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:27-31. doi: 10.1007/s00280-005-0096-2. Cancer Chemother Pharmacol. 2005. PMID: 16273356 Review.
-
Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.Breast Cancer Res. 2005;7(5):R753-64. doi: 10.1186/bcr1285. Epub 2005 Jul 27. Breast Cancer Res. 2005. PMID: 16168121 Free PMC article.
Cited by
-
Biologically informed NeuralODEs for genome-wide regulatory dynamics.Genome Biol. 2024 May 21;25(1):127. doi: 10.1186/s13059-024-03264-0. Genome Biol. 2024. PMID: 38773638 Free PMC article.
-
CHD4-induced up-regulation of ERα activity contributes to breast cancer progression.Genes Dis. 2023 Sep 15;11(3):101108. doi: 10.1016/j.gendis.2023.101108. eCollection 2024 May. Genes Dis. 2023. PMID: 38292202 Free PMC article. No abstract available.
-
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.J Clin Invest. 2024 Jan 2;134(1):e163242. doi: 10.1172/JCI163242. J Clin Invest. 2024. PMID: 37883178 Free PMC article.
-
Estrogen Receptor Signaling in Breast Cancer.Cancers (Basel). 2023 Sep 23;15(19):4689. doi: 10.3390/cancers15194689. Cancers (Basel). 2023. PMID: 37835383 Free PMC article. Review.
-
circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells.Cell Death Dis. 2023 Jul 31;14(7):482. doi: 10.1038/s41419-023-06006-5. Cell Death Dis. 2023. PMID: 37524698 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical